Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.

Mohammad I SalehSuhad Bani MelhimHanguin M Al-RamadhaniSameh Alzubiedi

Published in: European journal of drug metabolism and pharmacokinetics (2019)

Eltrombopag pharmacokinetic behavior was described using population bayesian approach. This model can be applied to optimize eltrombopag dosing in order to reduce the incidence of thrombocytopenia in HCV-infected patient receiving interferon-based therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
hepatitis c virus
prognostic factors
risk factors
case report
dendritic cells
stem cells
mesenchymal stem cells
bone marrow
cell therapy